Adcetris
brentuximab vedotin · CD30Three xenograft models from human HL and ALCL cell lines
Tivdak: animal efficacy model or human cells?
tisotumab vedotin · Tissue factor
Efficacy evidence
Cervical cancer patient-derived xenograft (PDX) models in mice
“In vivo, anti-tumor activity and/or tumor regression was seen in cervical cancer patient derived xenograft (PDX) models when mice were administered tisotumab vedotin at 4 mg/kg twice in the first week of study via intravenous dosing.”
Why that model
Tisotumab does not bind mouse, rat, rabbit, pig or dog TF
“Tisotumab did not bind to mouse, rat, rabbit, pig, or dog TF.”
Reviewer's view of the efficacy data
EMA: activity in 5 of 6 cervical PDX models; TF expression measured in only 1, so its influence is unclear
“For the cervical cancer PDX models, a positive effect of tisotumab vedotin was noted in 5 out of 6 models, primarily at dose of 2-4 mg/kg. It should be noted that TF expression was only determined for one out of six cervical cancer PDX models and it is therefore unclear how the level of TF expression has affected the results in these models.”
Same question, other ADCs
Besponsa
inotuzumab ozogamicin · CD22Subcutaneous xenograft and systemically disseminated ALL mouse models
Datroway
datopotamab deruxtecan · Trop-2Nude mouse xenografts of human pancreatic cancer, NSCLC and breast cancer
Decnupaz
pivekimab sunirine · CD123Two BPDCN patient-derived xenograft (PDX) models in NSG mice
Elahere
mirvetuximab soravtansine · FRαOvarian cancer xenograft mouse models (single IV dose)
Emrelis
telisotuzumab vedotin · c-Metc-Met-positive NSCLC cell line-derived and patient-derived xenograft mouse models
Enhertu
fam-trastuzumab deruxtecan · HER2HER2-positive breast cancer xenograft mouse models (e.g., KPL-4 in nude mice)
Kadcyla
ado-trastuzumab emtansine · HER2HER2+ xenografts (BT-474 EI, Calu-3) and MMTV-HER2 transgenic tumor model; growth inhibition in all three at 3 to 31 mg/kg
Mylotarg
gemtuzumab ozogamicin · CD33CD33+ HL-60 leukemia xenograft in mice: >80% tumor growth inhibition
Padcev
enfortumab vedotin · Nectin-4Nectin-4-expressing patient-derived bladder cancer xenografts (AG-B1, AG-B8) in mice: >75% tumor growth inhibition
Polivy
polatuzumab vedotin · CD79bHuman DLBCL and B-cell lymphoma xenografts in mice; in vitro Ramos cytotoxicity
Trodelvy
sacituzumab govitecan · Trop-2Mouse xenografts bearing human Trop-2-expressing tumours
Zynlonta
loncastuximab tesirine · CD19CD19-positive human Burkitt lymphoma (Ramos, Daudi) and DLBCL (WSU-DLCL2) xenografts in immunodeficient mice